CD40 signaling drives potent cellular immune responses in heterologous cancer vaccinations

Cancer Research

Volumn 77, Issue 8, 2017, Pages 1918-1926

  Nimanong, Supot ^a,b   Ostroumov, Dmitrij ^a   Wingerath, Jessica ^a   Knocke, Sarah ^a   Woller, Norman ^a   Gürlevik, Engin ^a   Falk, Christine S ^a,c   Manns, Michael P ^a   Kühnel, Florian ^a   Wirth, Thomas C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MAHIDOL UNIVERSITY   (Thailand)

^c German Center for Infectious Diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CANCER VACCINE; CD134 ANTIGEN; CD137 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; DENDRITIC CELL COAT VACCINE; GAMMA INTERFERON; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYGLACTIN; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD40 ANTIGEN; OLIGOPEPTIDE; TLR3 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 3;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ASSAY; HEPATOBLASTOMA; IC50; IMMUNOGENICITY; LIVER CELL DAMAGE; LUNG CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SARCOMA; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; AGONISTS; ANIMAL; C57BL MOUSE; COLORECTAL NEOPLASMS; DENDRITIC CELL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; PROCEDURES; TRANSGENIC MOUSE; TRANSPLANTATION; VACCINATION;

ANIMALS; ANTIGENS, CD40; CANCER VACCINES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGOPEPTIDES; TOLL-LIKE RECEPTOR 3; VACCINATION;

EID: 85018179484     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2089     Document Type: Article

References (36)

1. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482:405-9.
2. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400-4.
3. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer 2014;14:135-46.
4. Chen DS, Mellman I. Oncologymeets immunology: The cancer-immunity cycle. Immunity 2013;39:1-10.
5. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013;499:214-8.
6. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081-91.
7. Kowalewski DJ, Stevanovic S, Rammensee HG, Stickel JS. Antileukemia T-cell responses in CLL-We don't need no aberration. Oncoimmunology 2015;4:e1011527.
8. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
9. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
10. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
12. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015;348:803-8.
13. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
14. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82.
15. Butterfield LH. Cancer vaccines. BMJ 2015;350:h988.
16. Esfandiary A, Ghafouri-Fard S. MAGE-A3: An immunogenic target used in clinical practice. Immunotherapy 2015:7;683-704.
17. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Nat Cancer Inst 2014;106.
18. Brinkhoff B, Ostroumov D, Heemcke J, Woller N, Gurlevik E, Manns MP, et al. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. Eur J Immunol 2014;44:1213-24.
19. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005;11:748-56.
20. Pham NL, Badovinac VP, Harty JT. Adefault pathway of memoryCD8T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. J Immunol 2009;183:2337-48.
21. Pham NL, Pewe LL, Fleenor CJ, Langlois RA, Legge KL, Badovinac VP, et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proc Natl Acad Sci U S A 2010;107:12198-203.
22. Corbin GA, Harty JT. Duration of infection and antigen display have minimal influence on the kinetics of the CD4+ T-cell response to Listeria monocytogenes infection. J Immunol 2004;173:5679-87.
23. Badovinac VP, Hamilton SE, Harty JT. Viral infection results in massive CD8+T cell expansion and mortality in vaccinated perforin-deficient mice. Immunity 2003;18:463-74.
24. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS, et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-Term immunity tomalaria. Proc Natl Acad SciUS A 2008;105:14017-22.
25. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemo Pharm 1989;24:148-54.
26. Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM, et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther 2015;23:1630-40.
27. Horvath C, Andrews L, Baumann A, Black L, Blanset D, Cavagnaro J, et al. Storm forecasting: Additional lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 2012;12:740.
28. Rai D, Pham NL, Harty JT, Badovinac VP. Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J Immunol 2009;183: 7672-81.
29. Medina-Echeverz J, Ma C, Duffy AG, Eggert T, Hawk N, Kleiner DE, et al. Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage. Cancer Immunol Res 2015;3:557-66.
30. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572-6.
31. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-9.
32. Yanagisawa S, Koike M, Kariyone A, Nagai S, Takatsu K. Mapping of V beta 11+helper T cell epitopes onmycobacterial antigen in mouse primed with Mycobacterium tuberculosis. Int Immunol 1997;9:227-37.
33. Wirth TC, Harty JT, Badovinac VP. Modulating numbers and phenotype of CD8+ T cells in secondary immune responses. Eur J Immunol 2010; 40:1916-26.
34. Wirth TC, Martin MD, Starbeck-Miller G, Harty JT, Badovinac VP. Secondary CD8+ T-cell responses are controlled by systemic inflammation. Eur J Immunol 2011;41:1321-33.
35. Wirth TC, Xue HH, Rai D, Sabel JT, Bair T, Harty JT, et al. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity 2010;33:128-40.
36. Kayes T, Fang Y, Yu S, Downey E, Wang S, Braley-Mullen H. Agonistic anti-CD40 induces thyrocyte proliferation and promotes thyroid autoimmunity by increasing CD40 expression on thyroid epithelial cells. J Immunol 2013;190:3928-38.